Fig. 3. Effect of cyclophosphamide on tumor growth following DC vaccine. (A) Schematic representation of the experimental groups and schedule. Mice were subcutaneously implanted with 1 x 106 MC38/CEA2 cells in the right flank on 10 days. (B) After 10 days, the mice were subcutaneously vaccinated in the opposite flank either once (●), or twice (■), or thrice (▲) with 1×106 CEA peptide pulsed DC or mock DC (thrice: ○) or PBS (X) at intervals of one week. (C) After 10 days, the mice were intraperitoneal (i.p.) injected with cyclophosphamide 100 mg/kg followed 6 hr later by the subcutaneous (s.c.) injection of 1×106 CEA peptide pulsed DC on 10 days (once ●), 17 days (twice ■), and 24 days (thrice ▲), repectively. (D) Various dose (100: ●, 50: ▲, 25: ■, 12.5 mg/kg: ○) of cyclophosphamide i.p. followed 6 hr later by the s.c. injection of 1×106 CEA peptide pulsed DC: thrice weekly. The results represent the average values±SD of ten mice per group in a representative experiment of three separate experiments. The numbers in parentheses refer to the survival mice per total number of mice in each group. **P<0.01, *P<0.05.
© 2022 Korean J Clin Lab Sci
